| Name | Title | Contact Details |
|---|
Electrify America, LLC is a prominent electric vehicle (EV) charging network in the United States, established in 2016 as a subsidiary of Volkswagen Group of America. The company aims to promote Zero-Emission Vehicle (ZEV) adoption by creating a nationwide network of ultra-fast and convenient EV charging stations. As of August 2024, Electrify America operates over 950 charging stations with more than 4,250 DC fast charging connectors, making it the largest open DC fast-charging network in the country. The company focuses on providing reliable and accessible hyper-fast charging solutions, supporting multiple connector types, including CCS and CHAdeMO, with plans to add Tesla’s North American Charging Standard (NACS) connectors in 2025. Electrify America is committed to sustainability, ensuring that all energy supplied to drivers is backed by 100% renewable energy certificates, and aims for a net zero carbon footprint. Headquartered in Reston, Virginia, the company employs around 300 people and actively engages in community education to promote equitable electrification.
Introducing QXO.
Aim Sky High Academy is a Forbes featured, award-winning dance organisation featured in Forbes and Business Insider that aims to socially mobilise children and young people by teaching lifelong transferable skills through dance. Our students are current UK Hip Hop Dance Champions and have been used by Justin Bieber, Stormzy, Giggs and more. Awards won include: - Lloyds Bank School for Social Entrepreneurs Scale-Up Award 2016 - Social Enterprise UK Inspiring Youth Award 2015 - UDO World Champions 2014 - UDO European Champions 2014/15/16/19 - Barclays School for Start Ups Social Enterprise Winner 2013 ...and more. Come and follow our journey!
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
IQUW is a global specialty (re) insurer at Lloyds (syndicate 1856), underwriting complex risks and developing a new way to combine data, intelligent automation and human expertise to make smart decisions, fast. Led by a team of expert underwriters, we underwrite a diverse, multi-line product portfolio including Cargo, Cyber, Delegated Authority Property, D&F Property, D&O, Energy, Financial Institutions, Marine and Energy Liability, Political Violence, Terrorism and War, Property Treaty and Specialty Reinsurance. And because we are a Lloyds syndicate, all our policies come with an A+ rating from Lloyds. To connect with a member of the IQUW team, visit IQUW.com or to visit, you can find us at our HQ in 30 Fenchurch Street, London or at Box 64, 137 and 221 at Lloyds.